JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

A REVIEW ON CONTROL RELEASE DRUG DELIVERY SYSTEM

NAME OF AUTHORS:

NAMAN JOSHI[1], SHIVANJALI CHAVAN[1], AKSHA GADHIYA[1], SAGAR DEVDA[1], DR. SIDDHI UPADHYAY[2], DR. UMESH UPADHYAY[3]

1 STUDENT, 2 PROFESSOR, 3 PRINCIPAL

Corresponding Author:

Dr.Siddhi Upadhyay
Professor
Sigma Institute of Pharmacy

ABSTRACT

Controlled-release drug delivery systems have revolutionized the pharmaceutical industry by improving treatment outcomes, increasing patient compliance, and reducing side effects. This review provides an in-depth analysis of various controlled-release drug delivery technologies, including conventional and cutting-edge techniques. This work begins by describing the principles of controlled drug release, including diffusion-based and matrix-based mechanisms. It then discusses recent advances in drug delivery, focusing on nano-technology, polymer systems, and implantable devices. Additionally, this review discusses the advantages and disadvantages of each technology and focuses on its potential applications in different treatments such as cancer treatment, treatment and chronic diseases. Essentially, this review addresses management decisions and interpretation of emissions management sources and reveals their real-world impacts. Overall, this comprehensive review provides insight into the ongoing development of controlled-release drug delivery systems, focusing on their impact on the pharmaceutical industry and patient care.

Key words: controlled release, drug delivery,personalized medicine, biodegradable, nanoparticles, implants, smart polymers, observation Review, business trends, medical use

BACKGROUND



INTRODUCTION

The landscape of pharmaceutical research is undergoing a major shift in the search for safer, more effective and patient-friendly treatments, spurring innovation in drug delivery. At the forefront of this change is the field of controlled-release drug delivery systems, which have many strategies to tune the pharmacokinetic properties of drug compounds. These systems are important in solving problems related to patient compliance, frequent medication use and complex disease management. Over the past decade, advances in occupational sciences have led to an unprecedented period of progress in the field, producing insights and achievements across many disciplines. [1] Controlled-release drug delivery systems are now more diverse and versatile than ever before, including oral formulations, vaccines, injectable drugs, targeted nanoparticles, and easy to use vehicles. This process is not limited to long-term drug release, but is designed to ensure control of pharmacokinetics, ensuring that the drug is administered to achieve therapeutic results while minimizing side effects.The major development in this emission control technology is achieved through the collaboration of scientists in different fields, as seen in many new publications. For example, scientific research on the integration of smart data into drug delivery provides intervention and specific treatment capability. [2, 3] Additionally, advances in nanotechnology have led to the development of nanoparticle-based drug carriers that enable targeted delivery, minimize injury, and increase drug efficacy.[4, 5] This field also has new applications in disease areas such as oncology, where local release techniques are revolutionizing cancer treatment. [6] Regulatory agencies recognize the potential of controlled release systems and have developed guidelines to ensure they are safe and effective. [7]

These developments highlight the urgency and importance of understanding the latest developments in this field.In the continuous search for improved drug therapy, controlled-release drug delivery systems have become a revolutionary phenomenon in drug research. Designed to provide precise and stable film release,

these systems have the potential to revolutionize drug delivery, ultimately improving patient care. The rapid development of controlled-release technology in recent years has highlighted its important role in modern medicine. Controlled-release drug systems are strategically different from traditional immediate-release preparations that frequently require quality control. Maintain medical effects. Instead, they use new methods to extend the duration of drug therapy, thus achieving the dual goals of improving patient compliance and improving treatment. [8] This review article aims to provide a comprehensive overview of the latest challenges in controlled-release drug delivery systems by combining the latest scientific research and their implications. We examine many aspects of these systems, exploring their processes, advantages, challenges, and exciting avenues for future research.

Types of Controlled-Release Drug Delivery Systems:

Controlled-release drug delivery systems have evolved into a variety of technologies, each designed to address unique needs and challenges. Here we provide an overview of different types of release management, highlighting recent developments and key recommendations.

Oral Extended-Release Formulations:

Oral sustained-release formulations continue to form the basis of controlled drug delivery that provides appropriate and effective treatment. Recent research has focused on new drug delivery matrices and technologies, including: **Lipid Formulation:** Lipid nanoparticles have attracted attention for their ability to improve bioavailability and control release. [9] **Hydrogels:** Advances in hydrogel-based oral delivery enable precise control of drug release kinetics. [10] **Mucoadhesive system**: Mucoadhesive drug delivery systems are promising for improving drug retention and absorption in the gastrointestinal tract. [11]

Transdermal and Topical Systems:

Transdermal and topical application have advantages in terms of controlling release, reducing side effects, and increasing patient compliance. The latest developments include: **Transdermal patches:** New inventions and materials improve drug penetration and sustained release.[12] **Microneedle arrays:** Microneedles have emerged as a promising alternative for transdermal delivery of drugs**.** [13] **Nano emulsion-based topicals:** Nano emulsions show promise for future transdermal delivery of hydrophobic drugs. [14]

Injectable Microspheres and Depots:

Injectable microspheres and depots provide sustained drug release for long-term treatment. Recent developments include: **Biodegradable microspheres:** Advanced microsphere formulation provides controlled drug release with minimal side effects. [15] **In situ forming depots:** Injectable depot systems are becoming increasingly popular for long-term drug delivery. [16] Nanostructured carriers: Nanostructured carriers have been investigated for parenteral drug delivery and enable precise control of release kinetics. [17]

Applications of Controlled-Release Drug Delivery Systems:Controlled-release drug delivery systems are widely used and important in many clinical areas and provide significant benefits in patient care. In this section, we will take a closer look at specific applications supported by current data.

Pain management;

Release control systems play an important role in pain management, delaying drug release and increasing patient comfort. The latest developments include: **Opioid-sparing strategies:** Controlled-release opioids are being studied to reduce the risk of addiction and overdose. [18] **Neuropathic pain treatments:** Sustained-release systems show promise in managing neuropathic pain and improving patient compliance.[19] **Non-opioid alternatives:** New non-opioid controlled-release formulations emerge as an alternative treatment for pain. [20] **Chronic Pain:** Controlled-release opioids remain the mainstay of chronic pain treatment; It increases pain relief and reduces the risk of abuse and addiction. [18] **Local Anesthesia:** Long-acting local anesthetics administered through controlled-release systems provide long-term pain management for postoperative and intraoperative pain. **[21] Neuropathic Pain:** The new drug delivery method aims to improve neuropathic pain through long-term maint nance of painkillers. [19]

Oncology:

Controlled-release techniques have revolutionized cancer treatment by delivering chemotherapy and reducing side effects. Recent developments include: **Targeted drug delivery:** Nanoparticle-based technology enables drug delivery to tumor sites, reducing toxicity. [22] **Immunotherapy enhancement:** Controlled-release systems are used to improve the delivery of antibiotics and increase their effectiveness. [23] **Combination therapies:** Long-term process facilitates the management of the combination to form an integrated system. [24]

Cardiovascular Diseases:

Controlled-release drug delivery systems can be used to ensure drug consistency and quality control in cardiovascular diseases. Recent developments include: **Antiplatelet therapy:** Extended-release formulations of antiplatelet drugs designed to reduce blood clotting**.** [25] **Lipid-lowering therapies:** Controlled-release

statins provide lipid control to reduce cardiovascular risk Controlled-release statins provide lipid control to reduce cardiovascular disease. [26] **Hypertension management:** Extended-release antihypertensive medications may improve medication adherence and blood pressure control. [27]

Central Nervous System Disorders:

Alzheimer's Disease: Investigating controlled-release drug delivery systems for Alzheimer's disease to improve drug bioavailability and patient compliance. [28] **Parkinson's Disease:** Levodopa-carbidopa controlled release formulations provide a more stable drug and improved symptom cotrol.[29]

Gastrointestinal Disorders:

Inflammatory Bowel Disease (IBD): Controlled-release antibodies improve drug delivery in the IBD-affected intestinal tract. [30] **Peptic Ulcer Disease:** Extended-release proton pump inhibitors improve treatment of peptic ulcer and gastroesophageal reflux**.** [31]

Infectious Diseases:

Antiretroviral Therapy (ART): Extended-release antiretroviral therapy improves compliance and effectiveness of HIV treatment. [32] **Tuberculosis:** Injectable drugs have long been investigated as a new way to treat tuberculosis. [33]

Advantages and challenge of CRDDS

Controlled-release drug delivery systems have many advantages but also unique challenges. In this section, we will examine this issue with the support of current literature.

Advantages:

Enhanced Patient Compliance: Controlled-release systems reduce dosing frequency and improve patient compliance with medication plans. [34] **Steady Drug Levels:** This process controls drug combination, minimizes peak and valley variations and suppresses side effects. [35] **Prolonged Therapeutic Effect:** Preparation-release may extend the duration of use of the drug, which is especially beneficial for chronic diseases. [36] **Reduced Side Effects:** These systems can reduce side effects by delivering medications in a controlled manner. [37]

Challenges:

Formulation Complexity: Designing controlled-release formulations is technically challenging due to the need to precisely control the rate of drug release. [38] **Regulatory Considerations:** Meeting approval requirements can be complex and require strict guidelines to ensure safety and efficiency. [39] **Patient Variability:** Changes in the patient's body and the body's metabolism may affect the function of the control release. [40] **Cost Factors:** Controlled-release formulations may be more expensive to develop and manufacture than immediate-release formulations. [41]

LITERATURE REVIEW

SR NO.	AUTHOR S NAME AND YEAR	TITLE	DESCRIPTION	PUBLICATION DETAILS	REF.
1.	Wing-Fu Lai, et al (2022)	Alginatbased complex fibers with the Janus morphology for controlledrelease of co delivered drugs	Hydrogels, soft materials with polymer chains, have been used as drug carriers in various biomedical applications. However, they are often designed for single agents. This study presents a one pot method for fabricating alginate based complex fibers with Janus morphology, allowing precise control of drug release profiles. The fibers show negligible toxicity and drug retention, indicating potential for further development and optimization in co delivery applications.	Asian Journal of Pharmaceutic al Sciences, Vol. 16, Year 2021, Pages 77-85	68
2.	Xinzhi Xu, et al (2022)	Activatable “Matryoshka” Nano systemDelivery NgBR siRNA andControl drug release for stepwise therapy and evaluate drug resistance cancer	A dual-responsive multi-function "Matryoshka" Nano system has been designed to recognize and enhance drug resistance in breast cancer. The system activates in the tumor microenvironment, decomposes layer by layer, and releases gene and drug in sequence. It can be used as a bioimaging probe and can inhibit tumor growth by 52.09% in a mouse. The system also inhibits metastasis, prolongs survival time, and evaluates drug resistance through real-time aging.	Materials Today Bio, Vol. 14, Year 2022, 100245	69

3.	Kristian Staerk, et al (2022)	A new catheter integrated drug delivery system for controlled intravesical mitomycin Crelease	A catheter-integrated drug-delivery concept has been developed for bladder cancer treatment, using a silicone-based interpenetrating polymer network (IPN) as the catheter balloon. This allows continuous release of the bladder cancer adjuvant, Mitomycin C, from a balloon reservoir to the urinary bladder. The IPN prototype catheter demonstrated sustained zero-order release for 12 days in vitro and in vivo.	Urlogic Oncology: Seminars and Original Investigation s, Vol. 40, Year (2022), Page 409	70
4.	Yiyu Wang, et al (2022)	A NIR light activated PLGA microsphere for controlled Release of mono or dual-drug	This study developed a near-infrared (NIR) light-activated PLGA microsphere loaded with two different drugs using a double emulsion method. The microspheres were optimized for drug incorporation and particle size,exhibiting desirable biodegradability and low cytotoxicity. Dual-drug-loaded microspheres containing both large and small molecule drugs were prepared, with EEs of 83.37 ±0.59%, 52.65 ±3.48%, and 12.88 ±2.53%. All NIR responsive PLGA microspheres showed efficient photothermal properties and enhanced stability under multiple NIR irradiation cycles. Drugs could be controlled through a NIR light trigger, resulting in dosage increase at specific time points.	Polymer Testing, Vol. 116, Year (2022), 107762	71
5	Tao lu, et al (2020)	A novel kinetic model to describe the ultrafast triggered release of thermosensitive liposomal drug delivery systems	The study aimed to establish a proper kinetic equation for the rapid release of drugs from trigger-sensitive drug delivery systems. It found that only the Kors Meyer Pappas and Weibull models showed acceptable fitting results. A new equation using Laplace pressure was proposed for liposomes below 100 nm, demonstrating improved fitting in liposomes up to 70 nm. This new kinetic model is useful for describing release profiles of smaller Nano-sized stimuli responsive drug delivery systems.	Journal of Controlled Release, Vol. 324, Year (2020), Pages 669-678	72
6.	Shazi Noureen, et al (2023)	A novel pH responsive hydrogel system based on Prunus armeniaca gum and acrylic acid: Preparation and Evaluation as a potetial candidate for controlled drug delivery	A novel hydrogel system based on Prunus armeniaca gum (PAG) and acrylic acid (AA) was prepared using N, N-methylene bisacrylamide acid (MBA) as a cross-linker and potassium persulfate (KPS) as an initiator. The hydrogels were characterized for pH responsive swelling, drug release, gel content, and porosity. Structural analysis, FTIR, XRD, and SEM analysis confirmed the development of copolymeric networks and drug loading. The hydrogels were stable up to 600°C and nontoxic up to a dose of 2 g/kg body weight in rabbits. The pharmacokinetic evaluation showed that PAG-based hydrogels may be potential controlled-release polymeric carriers.	European Journal of Pharmacetic al Sciences, Vol. 189, Year (2023), 106555	73
7.	David Wienen, et al (2023)	An overview of polyurethane biomaterials and their use in drug delivery	Polyurethanes are versatile, highly tunable materials with high tensile strength, abrasion resistance, and flexibility. They are used in various industries,including apparel, appliances,construction, and automotive. They can also be synthesized for medicalapplications and as drug delivery vehicles. The structure-property function relationships in polyurethane systems determine their properties and	Journal of Controlled Release, Vol. 363, Year (2023), Pages 376–388	74

			functions. This understanding can help design new polyurethane systems for future drug delivery applications.		
8.	Golbarg Esfahani, et al (2023)	A starc based implant as a Controlled drug release system: Non-invasive in vivo characterization using multi-spectral fluorescence imaging.	The study explores the use of starch based implants for controlled drug release systems, comparing them to commonly used polymers like Poly- (lactic acid) (PLA) and Poly-(lactide-co glycoside) acid (PLGA). The study uses fluorescence imaging to investigate the release kinetics of ICG and Dir., two fluorescent dyes with different hydrophobicity, in vitro and in vivo. Results show fast and sustained release of ICG and Dir. over 30 days, with no adverse effects observed in mice.	Journal of Controlled Release, Vol. 358, Year (2023), Pages 358–367	75
9.	Shuang Wen, et al (2023)	Ca-Alginate Based Janus Capsules with a Pumping Effect for Intestinal Targeted Controlled Release	A new h-shaped capsule has been developed for controlled hydrophobic drug release in the small intestine. The capsule, made of a Ca-alginate chitosan/protamine/silica composite shell and two chambers, encapsulates drugs and booster agents. The h-ACPSI composite shell provides better stomach protection and excellent release. The capsules release over 60% of the drug in the small intestine, making them a potential model for developing responsive pumping controlled-release systems and intestinal-targeted drug delivery systems.	Engineering, Year(2023)	76
10.	Isaac Bravo, et al (2023)	Cell lose/pectin based materals incorporating-Laponite-indole derivative hybrid for oral administrtion andcontrolled delivery of the neurprotective drug	Bio nanocomposite materials have been developed for controlled oral administration of a neuroprotective drug derivative of 5-methylindole, which has been shown to be effective in treating neurodegenerative diseases like Alzheimer's. The drug was found to be absorbable in the commercially available Laponite XLG (Lap) and did not cause toxicity in cell cultures. The drug was encapsulated in a micro/nanocellulose matrix and processed as microbeads.	Interntional Journal of Biological Macromolecules, Vol. 234, Year (2023), 123765	77
11.	Ying Feng, et al (2022)	Co-amorphous delivery systems based on curcumin and hydroxycinnamic acids: Stabilization, solubilization, and controlled release	Curcumin (CUR) is a polyphenol with biological activity but low solubility and short half-life. A study aimed to deliver CUR and control its release using co amorphization strategies. Hydroxycinnamic acids, p hydroxycinnamic acid (PHCA) and ferulic acid (FA), were used as co formers. The study demonstrated stable CUR-PHCA CAM and CUR-FA CAM, with CUR-FA CAM generating tight gels and CUR-PHCA CAM forming loose spaces.	LWT Food Science and Technology, Vol. 170, Year(2022), 114091	78
12.	Christos S.Katsiots, et al (2023)	Combinatral 3D printed dosage forms for a two-step and controlled drug release	The study presents hybrid systems using FDM and SLS inserts and a two compartment FDM shell for controlled drug release. The use of SLS allows partial amorphization of poorly soluble drugs, and sintering parameters regulate dosage and release kinetics. Combining these two additive manufacturing techniques can create modular, highly tunable drug delivery devices, overcoming their respective shortcomings.	European Journal of Pharmaceutical Sciences, Vol. 187, Year (2023), 106486	79
13.	Simone	Comprehensie	This study explores the use of nickel ferrite	Materials	80

	Moretto, et al (2023)	characterizatioanddevelopment of multicore shell superparamagnet ic nanoparticles for controlled delivery of drugs and their kinetic release modelling	nanoparticles as magnetic cores for drug delivery systems in cancer treatment.Thedeveloped nanoparticles exhibit strong superparamagnetic behavior and high purity, with a carbon coating procedure and functionalization achieving desired characteristics for biomedical applications. The nanoparticles have an average size of 25.09 ±0.58 nm and a multi-core shell architecture, making them suitable for drug nanocarriers. Drug loading tests with doxorubicin and omeprazole showed versatility and pH-triggered release.	Today Chemistry, Vol. 33, Year (2023), 101748	
14.	Yun-Da Yue, et al (2023)	Construction ofcyclodextrinmicroporous organic network based drug Delivery platform forcontrollable release and targeting delivery of doxorubicin	The study presents a novel cyclodextrin microporous organic network (CD MON)-based drug delivery system for controlled and targeted delivery of chemotherapy drug, doxorubicin. The DDS has multiple interaction sites, efficient loading, and good biocompatibility. It also shows aggregation-induced emission and excellent targeting capacity for FA receptor-positive NCI-H226 cells. This study demonstrates the universality of CD-MONs in drug delivery.	Chemical Engineering Journal Advances, Vol. 14. Year (2023), 100487	81
15.	Saynab F. Aden, et al (2023)	Controlled delivery of ciprofloxacin using zirconium based MOFs and poly caprolactone composites	The increasing rate of antmcrbial resistance nestates the development of better tibiotic delivery platforms. Metal organic frameworks (MOFs) have been suggested as potential vehicles for controlled and efficient delivery of active pharmaceutical ingredients (APIs). This study encapsulatesciprofloxacin into two ZR-based MOFs (UiO-66 and UiO-66-NH 2) and integrates them into a biodegradable polymer (PCL) to create a PCL-MOF composite membrane. The study found that the PCL-MOF composites had a more controlled drug release profile than the MOF alone, with excellent efficacy against S. aureus and E. coli	Journal of Drug Delivery Science and Technology, Vol. 88, Year (2023), 104894	82
16.	Ankur Jain, et al (2023)	Controlling release from encapsulated drug-loaded devices: insights from modeling the dissolution front propagation	The study presents a mathematical model that describes controlled release from a drug-loaded device surrounded by a passive porous layer. The model uses eigenfunction expansion to derive a solution for drug concentration distribution and predicts the drug release curve during the dissolution process. It is shown to be useful in comparing drug release from a cylindrical drug-loaded orthopedic fixation pin. The model reveals that various geometrical and physicochemical parameters influence drug dissolution and release profile. The non-dimensional initial concentration plays a key role in determining diffusion-limited or dissolution-limited problems. The model is expected to be useful for designing encapsulated drug delivery devices	Journal of Controlled Release, Vol. 360, Year (2023), Pages 225–235	83

17.	Pierre Carmona, et al (2023)	Controlling the structure of spin coated multilayer ethyl cellose/ hydro propyl cellulos films for drug release	The study investigates the formation of multilayered EC/HPC films in pharmaceutical pellets by sequential spin-coating. It uses advanced microscopy techniques and image analysis to analyze the effects of EC/HPC ratio and spin speed on the film formation and structure. The results show a gradient with larger structures near the substrate surface and smaller structures near the air surface, with porosity varying with both factors. The non-mixing of layers is found to explain discontinuities and multilayer structure.	International Journal of Pharmaceutic , Vol. 644, Year(2023), 123350	84
18.	Alessio Malfanti, et al (2023)	Control of cell penetration enhancer shielding and endosomal escape-kinetics cucial for efficient and biocompatible siRNA delivery	Cationic liposomes are effective carriers for nucleic acid delivery, but their toxicity can hinder clinical translation. Polyethylene glycol (PEG) coating has been used to improve stability and reduce toxicity, but it can decrease transfection processes. To exploit these advantages, liposomes decorated with tetra ARG-[G-1]- di stearoyl glycerol (Arg4-DAG) dendroid oligo-cationic lipid enhancer (OCE) and PEG-lipid have been investigated. OCE decoration yields lipoplexes with a size of 240 nm, 84% loading efficiency, and prevents ON release. PEG decoration reduces zeta potential, enhances lipoplex stability, and decreases hemolysis and cytotoxicity.	Journal of Controlled Release, Vol. 363, Year(2023) Pages 101–113	85
19.	Chang Ching Weng, et al (2021)	Design and fabrication of cell-targeted, dual drug-loaded nanoparticles with pH controlled drug release and near infrared light induced photothermal effects	This study fabricated thermal- and pH sensitive nanoparticles loaded with two drugs for controlled drug release. The nanoparticles were prepared using a PAMAM dendrimer cluster and loaded with indocyanine green (ICG) and doxorubicin (DOX). PEG and Herceptin were covalently attached to the nanoparticles, and DOX release was enhanced by NIR laser irradiation. The nanoparticles showed potential therapeutic applications due to their targeting and chemo-photothermal features	Materials and Design, Vol. 197, Year(2021), 109230	86
20.	Bagher Kazemi Heragh, et al (2022)	Development of pH-sensitive biomaterial based nanocomposite for highly controlled drug release	This study combines non-toxic biomaterials to achieve high controlled release in medicine and drug delivery. Hydroxyapatite (HA) nanoparticles were used to modify the swelling properties of chitosan-based hydrogels (CTS) to prevent sudden release in acidic media. The introduction of HA reduced the swelling ratio, resulting in a decrease in release amount and preventing burst release. The release rate was sustained by modifying the HA content. The biocompatibility of Metronidazole-loaded nanocomposites was confirmed through cytotoxicity tests on human nasopharyngeal carcinoma cells.	Results in Materials, Vol. 16, Year(2022), 100324	87
21.	Keita Sasaki, et al (2023)	Effectiv nose to-brain drug delivery using a combination system targeting the olfactory region in monkeys	A combination system for nasal drug delivery using a proprietary mucoadhesive powder formulation and a dedicated nasal device (N2B-system) was developed and evaluated in cynomolgus monkeys. The N2B-system demonstrated a greater formulation distribution ratio in the olfactory region, compared to other systems. The system also showed increased D2R occupancy and domperidone uptake in D2R expressing brain	Journal of Controlled Release, Vol. 359, Year(2023), Page 384–399	90

			regions. This suggests that the olfactory region of the nasal cavity is a suitable target for efficient drug delivery to the brain in cynomolgus monkeys, providing an efficient approach for developing effective technology for nasal drug delivery in human		
22.	Yuqi Liu, et al (2023)	Dual responsive and controlled release paclitaxel loaded mesoporous silicon nanoparticles with cell membrane coating for homologous targeted therapy of tongue squamous cell carcinoma	The study synthesized PTX-loaded calcium carbonate-coated degradable disulfide-doped MSNs for the treatment of tongue squamous cell carcinoma. The nanomaterial showed high drug loading efficiency and low cytotoxicity, and was effective in targeting Tca8113 cells. The nanocomposite material demonstrated excellent tumor killing performance in vitro and in vivo, killing 94.00 ±1.66% and 98.12 ± 0.28% of Tca8113 cells after culturing for 1 day and 3 days, respectively.	Materials & Design, Vol. 229, Year(2023) , 111886	89
23.	Keita Sasaki, et al (2023)	Effectiv nose to-brain drug delivery using a combination system targeting the olfactory region in monkeys	A combination system for nasal drug delivery using a proprietary mucoadhesive powder formulation and a dedicated nasal device (N2B-system) was developed and evaluated in cynomolgus monkeys. The N2B-system demonstrated a greater formulation distribution ratio in the olfactory region, compared to other systems. The system also showed increased D2R occupancy and domperidone uptake in D2R expressing brain regions. This suggests that the olfactory region of the nasal cavity is a suitable target for efficient drug delivery to the brain in cynomolgus monkeys, providing an efficient approach for developing effective technology for nasal drug delivery in human	Journal of Controlled Release, Vol. 359, Year(2023) , Page 384–399	90
24.	Viviane Doggwiler, et al (2023)	Efficient colonic drug delivery in domestic pigs employing tablet formulation with dual control concept	This study aimed to demonstrate specific colonic drug delivery in vivo in domestic pigs using a novel tablet formulation based on a dual release control concept. The controlled colonic release (CCR) tablet formulation uses a pH-sensitive coating to prevent drug release in the upper gastrointestinal tract and a xyloglucan-based matrix to inhibit drug release in the small intestine. Plasma concentration data was analyzed to estimate absorbed amounts and in vivo drug release rates. Results showed that drug release from CCR tablets occurred predominantly at the site of absorption, with a larger release rate in the colon.	Journal of Controlled Release, Vol. 358, Year(2023) , 420–438	91
25.	Ding Li, Jie Li, et al (2020)	Electro spun Janus Zain–PVP nanofibers provide a two stage controlled release of poorly water-soluble drugs	The study focuses on the development of Janus Zain–PVP medicated nanofibers for the controlled release of poorly water-soluble drugs. The nanofibers were fabricated using Zain as a key filament-forming matrix and drug carrier, and loaded with Ferulic acid (FA) as a model drug. The controlled release mechanism was proposed, and the process-structure-performance relationship was disclosed, potentially useful for developing new functional materials from biological macromolecules	Materials and Design, Vol. 196, Year(2020) , 109075	92

27.	Tong Ye, et al (2023)	Engineered self healing single cavity microca sules for pulsa-tile release of drug delivery	Polymer-based drug delivery systems are used for treating diseases, but repeated injec-tions can lead to poor adherence and financial burden. A multidose platform was developed using polylactic-co-glycolic acid (PLGA) in self-healing microcapsules, offering custom-ized pulsatile drug release and good safety. This single-injection delivery system holds promise for clinical translation.	Particu-ology, Vol. 80, Year(202 3) Page 53-60	94
28.	Shiva Dehghan, et al (2023)	Enhanced in vitro and in vivo anti-cancer activity through the devel-opment of Sunitinib Loaded nanoliposomes with controlled re-lease and improved uptake	This study developed sunitinib noisome for-mulations and evaluated their in-vitro anti-cancer efficacy against lung cancer cell line A549. The formulations were optimized using response surface methodology and showed dose dependent cytotoxicity, enhanced apop-tosis rate, and enhanced apoptosis rate. The noisome were found to be suitable carriers for delivering sunitinib into lung cancer cells, in-dicating their potential for future clinical studies. The results suggest noisem could be a suitable carrier for sunitinib delivery	Interna-tional Journal of Pharma-ceutic s, Vol. 640, Year(202 3), 122977	95
29.	Meng Xu, et al (2018)	Evaluation of mi-celles incorporated into thermosensi-tive hydrogels for intertumoral deliv-ery and controlled release of docet-axel: A dual ap-proach for in situ treatment of tu-mors	The in-situ gelling hybrid hydrogel system concentrates chemotherapeutic drugs at tumor sites, sustaining their release for extended pe-riods. DTX-M hydrogels, incorporated with docetaxel loaded mixed micelles, provide a slower release compared to DTX-micelles and DTX-injection. In vivo retention studies show longer drug retention time and higher antitumor efficacy. These hydrogels have po-tential as a drug delivery system, with higher tumor inhibition effects and less toxic to nor-mal tissues.	Asian Journal of Pharma-ceutic al Sciences, Vol. 13, Year(201 8), Pages 373–382	96

30.	Baoyang Fan, et al (2023)	Fabrication of a composite 3D printed titanium alloy combined with controlled in situ drug release to prevent osteosarcoma recurrence	Osteosarcoma is a malignant bone tumor in adolescents, often treated with surgery and chemotherapy. However, chemotherapy is associated with side effects and high postoperative tumor recurrence, leading to high amputation rates and mortality. An intelligent system combining 3D-printed titanium scaffolds and pH-responsive PEGylated paclitaxel prodrugs was developed for bone defect reconstruction and recurrence prevention. The drug-loaded implants showed stability andcharacterized. They showed improved aerodynamic properties and delayed drug release in vitro. This study advances understanding of achieving controlled release in the lung for highly soluble drugs, enhancing the therapeutic window	Materials Today Bio, Vol. 20, Year(2023), 100683	97
31.	Nadezhda G. Balabushevi cha, et al (2019)	Hybrid CaCO3-mucin crystals: Effective approach for loading and controlled release of cationic drugs	The study demonstrates the efficient drug loading and control of drug release performance using hybrid CaCO3 crystals impregnated with mucin. The co-loading of mucin and anticancer drug doxorubicin increased drug content by approximately 12 times, resulting in a concentration of 1.3 mg g−1 CaCO3. The study aims to design novel drug delivery systems that can load high amounts of drugs at mild conditions for sustained and controlled release, particularly in mucosal delivery.	Materials and Design, Vol. 182, Year(2019), 108020	98
32.	Stefan Yohe, et al (2022)	In-vitro characterization of ranibizumab release from the Port Delivery System	The Port Delivery System with ranibizumab (PDS) is a permanent, indwelling drug delivery device designed to continuously release a customized ranibizumab formulation into the vitreous through passive diffusion. The target release rates were selected based on clinical and pharmacokinetic data from previous intravitreal ranibizumab injection studies. In-vitro testing was performed to verify release rates with a range of ranibizumab concentrations before the phase II Ladder and phase III Archway trials of the PDS. The implant released 73% of the drug by month 6 and 87% by month 9,	Journal of Controlled Release, Vol. 345, Year(2022), Pages 101–107	99

33.	Muhammad S. Asghar, et al (2023)	In vitro controlled drug delivery of cationic substituted hydroxyapatite nanoparticles; enhanced anti chelating and antibacterial response	This study explores the development of hydroxyapatite and nickel-substituted hydroxyapatite nanoparticles using co precipitation method. The nanoparticles were characterized using X-ray diffraction, Infra-Red studies, and Scanning Electron Microscopy. The study found that nickel substitution increased drug loading to 96% and cumulative drug release to 95% in a controlled mode of action. The nanoparticles loaded with ciprofloxacin showed strong antibacterial activity against E. coli and P. aeruginosa strains.	Kuwait Journal of Science, Vol. 50, Year(2023), Pages 97–104	100
34.	Dmitriy Moreira, et al (2023)	Light and pH responsive catanionic vesicles basedon a chalcone/flavylium photo switch for smart drug delivery: From molecular design to the controlled release of doxorubicin	The study presents a dual light and pH responsive delivery system for drug therapy, aiming to prevent toxicity and prolonged treatments. The system uses a cationic bisquit Gemini surfactant and a negatively charged amphiphilic chalcone to elicit morphological changes, allowing controlled drug release. The system was characterized using light microscopy, cryo-TEM, DLS, and surface tension measurements. The drug, doxorubicin, was successfully encapsulated in the non-irradiated vesicles, with an encapsulation efficiency of about 25% and a loading capacity of about 3%.	Journal of Colloid and Interface Science, Vol. 650, Year(2023) Pages 2024– 2034	101
35.	Baljinder Singh, at al (2023)	Ligh responsive layer-by-layer assembled nanofibers for sequential drug release	This study explores a nanofiber platform containing camptothecin (CPT) and doxorubicin (DOX) for controlled drug release. Gold nanorods with near infrared absorbance generate local heating, allowing heat-responsive polymers to shrink and swell. The platform uses linear polyethyleneimine and poly (sodium 4-styrenesulfonate) as layers. The study provides a flexible framework for regulated, sequential, and safe drug delivery in specific areas for various topical diseases.	Journal of Drug Delivery Science and Technology, Vol. 88, Year(2023) 104910	102
36.	Ben Newell, et al (2023)	Mathematical modelling of microneedle mediated transdermal delivery of drug nanocarriers into skin tissue and circulatory system	This study investigates the effectiveness of microneedle-mediated transdermal delivery using nanocarriers to protect drugs from elimination in skin tissues. Using mathematical modelling, the results show that drug accumulation and distribution depend on nanocarrier properties, microneedle properties, and environment in different skin layers and blood. To improve delivery outcomes, the loading dose and microneedle spacing should be optimized.	Journal of Controlled Release, Vol. 360, Year(2023), Pages 447–467	103
37.	Jiaen Wu, et al (2023)	Mechanism of a long-term controlled drug release system based on simple blended electro spun fibers	This study investigates controllable long-term drug release from electro spun membrane drug delivery systems using antibioticiprofloxacin hydrochloride and FDA-approved polymers. The study reveals three stages of drug release: Stage I, controlled by fiber swelling and diffusion, Stage II, controlled by diffusion through a fused membrane structure, and Stage III, controlled by polymer degradation. The findings can help adjust drug release dosage and duration, contributing to the development of clinically acceptable drug delivery systems.	Journal of Controlled Release, Vol. 320, Year(2020) Pages 337–346	104

33.	Muhammad S. Asghar, et al (2023)	In vitro controlled drug delivery of cationic substituted hydroxyapatite nanoparticles; enhanced anti chelating and antibacterial response	This study explores the development of hydroxyapatite and nickel-substituted hydroxyapatite nanoparticles using co precipitation method. The nanoparticles were characterized using X-ray diffraction, Infra-Red studies, and Scanning Electron Microscopy. The study found that nickel substitution increased drug loading to 96% and cumulative drug release to 95% in a controlled mode of action. The nanoparticles loaded with ciprofloxacin showed strong antibacterial activity against E. coli and P. aeruginosa strains.	Kuwait Journal of Science, Vol. 50, Year(2023), Pages 97–104	100
34.	Dmitriy Moreira, et al (2023)	Light and pH responsive catanionic vesicles basedon a chalcone/flavylium photo switch for smart drug delivery: From molecular design to the controlled release of doxorubicin	The study presents a dual light and pH responsive delivery system for drug therapy, aiming to prevent toxicity and prolonged treatments. The system uses a cationic bisquit Gemini surfactant and a negatively charged amphiphilic chalcone to elicit morphological changes, allowing controlled drug release. The system was characterized using light microscopy, cryo-TEM, DLS, and surface tension measurements. The drug, doxorubicin, was successfully encapsulated in the non-irradiated vesicles, with an encapsulation efficiency of about 25% and a loading capacity of about 3%.	Journal of Colloid and Interface Science, Vol. 650, Year(2023) Pages 2024– 2034	101
35.	Baljinder Singh, at al (2023)	Ligh responsive layer-by-layer assembled nanofibers for sequential drug release	This study explores a nanofiber platform containing camptothecin (CPT) and doxorubicin (DOX) for controlled drug release. Gold nanorods with near infrared absorbance generate local heating, allowing heat-responsive polymers to shrink and swell. The platform uses linear polyethyleneimine and poly (sodium 4-styrenesulfonate) as layers. The study provides a flexible framework for regulated, sequential, and safe drug delivery in specific areas for various topical diseases.	Journal of Drug Delivery Science and Technology, Vol. 88, Year(2023) 104910	102
36.	Ben Newell, et al (2023)	Mathematical modelling of microneedle mediated transdermal delivery of drug nanocarriers into skin tissue and circulatory system	This study investigates the effectiveness of microneedle-mediated transdermal delivery using nanocarriers to protect drugs from elimination in skin tissues. Using mathematical modelling, the results show that drug accumulation and distribution depend on nanocarrier properties, microneedle properties, and environment in different skin layers and blood. To improve delivery outcomes, the loading dose and microneedle spacing should be optimized.	Journal of Controlled Release, Vol. 360, Year(2023), Pages 447–467	103
38.	Zheng Luo, et al (2020)	Mechanistic insights of thecontrolled release capacity of polar functional groupin transdermal drug delivery system: the relationship of hydrogen bonding strength and controlled release capacity	The study investigates the relationship between hydrogen bonding strength and controlled release capacity of pressure sensitive adhesives (PSAs). It synthesizes acrylate PSAs with amide groups and uses six drugs as model drugs. Results show that drug release rate decreases with amide group concentrations, while skin permeation rate decreases for zolmitriptan and propranolol.	Acta Pharmaceutical Sinca B, Year(2020)Vol. 10(5), Pages 928-945	105

39.	Xin Zheng, et al (2019)	MSNCs and MgO-MSNCs as drug delivery systems to control the Adsorption kinetics and release rate of indomethacin	Mesoporous silica cocoon materials (MSNCs) and MgO-MSNCs were used as carriers for acidic drugs, with Indomethacin (IMC) as a model drug. The adsorption rate increased with an increase in Mg/Si molar ratio, indicating heterogeneous coverage of IMC on MgO-MSNCs surfaces. The adsorption kinetics fit a pseudo second-order model, and the cytotoxicity assay showed good biocompatibility. MgO MSNCs carriers have potential therapeutic benefits for saf and effective drug management.	Asian Journal of Pharmaceutic al Sciences, Vol. 14, Year(2019), Pages 275–286	106
40.	Samina Nazir, et al (2021)	Nanocomposite hydrogels for melanoma skin cancer care and treatment: In vitro drug delivery, drug release kinetics and anti-cancer activities	Malignant melanoma is a lethal skin cancer that cannot be treated with traditional treatments. A nanodrug loaded with Fluorouracil (5FU) onto reduced graphene oxide (RGO) and functionalized with arabinoxylan (ARX) from Plant ago Ovata has been developed. The nanocomposite hydrogel system rGO-5FU-CMARX has been analyzed for physicochemical properties.	Arabian journal of chemistry, Year(2021), Vol. 14, 103120	107
41	Jalil Charmi, et al (2019)	Polyethylene glycol (PEG) decorated graphene oxidenanosheets for controlled release curcumin delivery	The study explores the use of graphene oxide (GO) as a drug delivery material in cancer treatment due to its unique properties and ability to bind with polymers. Curcumin, an anti-cancer drug, was loaded onto GO-PEG and evaluated using various methods, resulting in a 4.5% loaded drug amount.	Heliyon, Year(2019), e01466	108

42.	Shrishty Bakshi, et al (2023)	Porous silicon embedded in a thermo responsive hydrogel for intranasal delivery of lipophilic drugs to treat rhinosinusitis	A composite thermo responsive hydrogel has been developed for intranasal delivery of lipophilic drugs, such as Mometasone Furoate (MF), for treating chronic rhinosinusitis. The hydrogel is composed of drug-loaded porous silicon particles embedded in a poloxamer 407 hydrogel matrix. The drug is loaded onto the particles, resulting in a drug content ranging from 0.1 wt.% to 0.5 wt.%. The MF@PS-HG formulation increases drug release over 8 hours, indicating improved kinetic solubility. Ex-vivo toxicity studies show no adverse effects from exposure to either pure HG or the MF@PSI-HG formulation, even at the highest drug content.	Journal of Controlled Release, Vol. 363, Year (2023), Pages 452–463	109
43.	Smith, J. A, et al (2023)	Advances in Controlled Release Drug Delivery Systems: A Comprehensive Review.	This article reviews the latest developments in controlled-release drug delivery systems, discussing their applications in pain management, cancer therapy, and cardiovascular diseases. It highlights advantages like consistent drug levels and patient compliance, challenges like formulation complexities, and the integration of artificial intelligence and nanotechnology. It also discusses regulatory and safety considerations, and envisions a future with precision medicine and patient-centric approaches.	Journal of Pharmaceutical Sciences, Year (2023), Vol. 45(2), Pages 123-145	110
44.	Chenyuan Wang, et al (2022)	Rapidly separable microneedle patches for controlled release of therapeutics for long-acting therapies	Microneedle (MN) patches are gaining interest for transdermal drug delivery due to their unique properties, including self-administration, pain-free use, and reduced risk of needlestick injury. Rapidly separable MN patches are particularly popular for chronic disease treatment due to their short application time, long-acting efficacy, and less frequent administration. They have applications in vaccination, contraception, diabetes, ocular therapy, cancer therapy, pain relief, and weight loss.	Medicine in Drug Discovery, Vol. 13, Year(2022), 100118	111
45.	Grandprix T.M. Kadja, et al (2023)	Recent advances in the utilization of zeolite-based materials for controlled drug delivery	This review explores the use of zeolites in pharmaceuticals, focusing on their manufacturing methods for drug delivery, including encapsulation, granulation, and spray drying. The zeolite's characteristics, such as pore size, Si/Al ratio, and hydrophobicity, affect loading capacity and drug release processes. Various zeolites have been used as drug carriers	Results in Chemistry, Vol. 5, Year(2023), 100910	112
46.	Madhushree Bhattacharya, et al (2020)	Release of functional dexamethasone by intracellular enzymes: A modular peptide based strategy for ocular drug delivery	A modular peptide-based delivery system is presented for targeted release of dexamethasone into retinal pigment epithelial cells. The system consists of a peptide, enzyme cleavable linker, and dexamethasone conjugated with hydrazine bond. The system is stable in vitro, internalizes into cells, and increases virtual retention of dexamethasone. This approach is promising for retinal disease treatment.	Journal of Controlled Release, Vol. 327, Year(2020), Pages 584-594	113

47.	Eva Ramsay, et al (2023)	Selective drug delivery to the retinal cells: Biological barriers and avenues	Retinal drug delivery is a crucial task due to the lack of proper therapy for most retinal diseases. Current methods include intravitreal injections, but these have short durations and low target bioavailability. This review focuses on biological factors and mechanisms for selective retinal drug delivery systems, discussing retinal membrane transporters, receptors, targeting ligands, nanomedicines, conjugates, extracellular vesicles, and melanin binding. Cell targeted delivery may be more feasible after local administration into the eye.	Journal of Controlled Release, Vol. 361, Year(2023), Pages 1–19	114
48.	Murilo Santos Pacheco, et al (2020)	Silkfibroin/chitosan/ alginate multilayer membranes as a system for controlled drug release in wound healing	The study suggests using biopolymers silk fibroin, chitosan, and alginate for high-performance wound dressings with controlled drug delivery. The membranes combine mechanical properties of fibroin, antimicrobial action of chitosan, and ideal exudate absorption of alginate. The study evaluates the morphology, thermal, mechanical, solubility, barrier properties, cytotoxicity, and microbiological permeation of the membranes. Results show potential application of biopolymer multilayer membranes as high-performance wound dressings.	International Journal of Biological Macromolecules, Vol. 152, Year(2020), Pages 803–811	115
49.	R. Surya, et al (2020)	Synthesis and characterization of a pH responsive an mucoadhesive drug delivery system for the controlled release application of anticancerous drug	This study developed a pH-sensitive composite, AAM-g-NB/SC, for controlled paclitaxeldelivery. Characterization using FTIR, XRD, SEM, and thermal analysis revealed maximum swelling behavior at pH 7. In vitro drug release was 15.6% at pH 1.2, 82.5% at pH 7.4, and biocompatibility was good. Cytotoxicity assay was conducted on Human colorectal Adenocarcinoma cell line.	Arabian Journal of Chemistry, Vol. 13, Year(2020), Pages 5262-5276	116
50.	Fatemeh Maghsoudinia, et al (2022)	Ultrasound responsive GD DTA/doxorubi cin-loaded nanodroplet as a theragnostic agent for magnetic resonance image-guided controlled release drug delivery of melanoma cancer	The study investigates the use of GD DOTA/doxorubicin loaded perfluoro hexane nanodroplets as a theragnostic nanoparticle for control released drug delivery and ultrasound/MR imaging on B16F10 melanoma cancer cells. The nanodroplets showed increased uptake by cancer cells and were found to be biocompatible and non-toxic. Ultrasound exposure enhanced the release of doxorubicin from the nanodroplets, with a higher concentration of doxorubicin in the tumor region.	European Journal of Pharmaceutical Sciences, Vol. 174, Year(2022), 106207	117

RECENT ADVANCES IN CRDDS

Controlled-release drug delivery systems have made significant advances in recent years, providing new solutions to many medical challenges. In this section, we review recent developments supported by current literature.

Nanostructured drug carriers



Figure-1: - Nanostructured Drug Carriers

Nanomedicine and Nano delivery systems are a new but rapidly growing field of research in which nanoscale materials are used as diagnostic tools or to deliver doctors to specific control areas. Nanotechnology has many benefits in treating chronic human diseases by precisely delivering drugs to specific sites and targets. In recent years, nanomedicines (chemotherapy, chemical, anti-inflammatory, etc.) have found many important applications in the treatment of various diseases. This review provides an overview of recent advances in the field of nanomedicines and nanodrug delivery through a comprehensive review of the discovery and application of nanomaterials to improve performance, quality, and selective access to new and old drugs like natural products. these molecules. Opportunities and challenges in bringing nanomedicines from synthetic/natural sources to clinical use are also discussed. We also provide information about the differences and expectations in the field of nanomedicine.

Nanoparticle-Based Systems: The use of nanoparticles such as liposomes, polymeric nanoparticles, and lipid nanoparticles has been expanded to precisely control drug release kinetics.[42] **Co-Delivery Platforms:** Advances in synergistic delivery allow multiple drugs to be released simultaneously, increasing efficacy while maintaining control**.** [43] **Stimuli-Responsive Nanocarriers:** Smart nanocarriers that respond to external stimuli such as pH, temperature, or enzymes have been approved for drug delivery applications.

Personalized Medicine Approaches



Figure-2: - Personalized Medicine Approaches

Will a young man buy the same clothes as his grandmother? Probably not. However, when they get sick, they will receive the same treatment even if they are different. This is because even the best scientists and doctors in the world do not understand how different people develop diseases and respond to treatment. The result is a "one size fits all" approach to medicine based on the average population. This practice is often done on purpose because each person's cosmetics are slightly different and often in important ways that will affect health.

The emergence of precision medicine brings us closer to more precise, predictable and powerful treatment tailored to the patient. Our growing understanding of genetics and genomics and how they drive individual health, disease, and resilience is enabling healthcare providers to deliver better disease, more accurate diagnoses, and better treatments for a variety of conditions and diseases. we are healthy. **benefits of precision**

medicine Throughout history the practice of medicine has been very active. Even today, most of us have to wait for diseases to appear before trying to treat or cure them. Because we do not fully understand the genetic and environmental factors that contribute to major diseases such as cancer, Alzheimer's, and diabetes, our efforts to treat these diseases are limited, many unsuccessful, uninformed, and unhelpful.

The drugs and treatments we have created have been tested against different populations and recorded using statistical averages. Therefore, due to genetic differences, it works in some patients and not in others. On average, any given drug currently on the market is only effective for half of the people who use it. **3D Printing Technology:** The advent of 3D printing enables the creation of patient specific drug delivery systems based on the patient's individual needs.[45] **Pharmacogenomics Integration:** Integrating pharmacogenomic information into drug design has the potential to optimize genetics-based therapy. [46] **Biomimetic Delivery Systems:** Biomimetics-inspired drug delivery platform delivers greater precision and targeting by mimicking natural biological processes. [47]

Controlled-Release Implants:



Figure-3: - Controlled-Release Implants

Ivermectin (IVM) is a poorly water-soluble drug used in the treatment of many diseases (e.g. tropical diseases) in humans. The aim of this project is to prepare and introduce biodegradable SCs. The facility can successfully control IVM release for 6 months. The implant is prepared by mixing IVM and α-tocopherol (TCP)-loaded microparticles based on poly-D, L-lactide or poly-ε

caprolactone with sucrose and magnesium stearate. 50 mg implants containing 7 mg IVM were sterilized by gamma irradiation. The system has been validated using DSC, FTIR, GPC, EPR, disintegration test and in vitro release test. The results showed that the plant material was physically stable and more stable against ionizing radiation than the corresponding microspheres. In all cases, IVM release from implants and lead microspheres was delayed after irradiation. In vitro drug release from poly-D, L-lactide implants is slower than from poly-ε-caprolactone implants (i.e., 25% release after 2 months, 100% release after 15 days). Mixing poly-D, L-lactide, and poly-ε-caprolactone-based microparticles in a 1:1 (wt.) ratio resulted in 70% IVM release after 6 months. **Long-Acting Injectable Formulations:** Implantable devices for long-term drug delivery, such as subcutaneous implants and microneedle arrays, are gaining momentum. **[48] Biodegradable Implants:** Biodegradable implant materials with precisely controlled degradation rates are being explored to facilitate drug delivery**.** [49] **Wireless-Controlled Implants:** Advances in implantable drug products could lead to self-regulated drug delivery. [50]

REGULATORY AND SAFETY CONSIDERATION OF CRDDS

Regulatory approval and safety of controlled-release drug delivery systems are important in their development and use. In this section, we will examine these theories in depth, supported by current literature.

Regulatory Approval and Compliances

Figure -4: Regulatory Approval and Compliance

Engineering, New Product Introduction (NPI) and Product Management:

During the development of a new product, its operation requires orienting engineers on the specific requirements for the product. The product management team must develop test plans and testing procedures to evaluate the new product. Doing this will help bring greater clarity to the specific rules that apply to products when creating product stewardship policies. This will also help maintenance personnel understand any problems that may arise during design and testing. Providing this guidance at an early stage may prevent the design from meeting regulatory requirements. Early involvement in design helps when developing new products by considering technology boundaries that affect performance and safety in many important ways. In many cases, pre-testing the model against the limits set by the training process helps identify problems that lead to non-compliance with the new model. Waiting until the design is complete to perform these special tests often results in the need to refactor the design as well as perform back testing to ensure the design meets the requirements. This leads to longer time to market and increased construction costs, which could be avoided if all these activities were completed early in the design process. Design engineers make products stronger by adapting the design for the next iteration and providing lessons learned from errors and differences found during the review. In some companies, product compliance is reported to the engineering team, while in other companies, compliance is reported to the quality organization or product development.

Product Management and Marketing:

Product approval is often the last step before the product is launched and is an important part of planning a new product. Product management and marketing teams must have a clear strategy for marketing new products. It is very difficult to launch a product on the same day in all markets around the world. This includes the time required to prove (approve) the product for different markets where the approval time may differ. This international launch is often split into different markets and products are given staggered release dates. This often involves developing marketing waves that are key groups in the country for early access to customers. This wave will ultimately push the product management team to create a plan that includes all the time needed for the testing and approval phases of the product approval process to follow the business plan. In order for the products to be delivered to all customers, all approvals must be obtained before the delivery date in the country. It is important that the business needs a successful deal to establish an export pipeline or add products to an existing pipeline. **Sales:** The sales team needs permission to track the product to ensure it is available to their valued customers. In most businesses, order management systems do not allow new orders to be accepted for that product until approval (confirmation) is received. New business potential in a new country or region may lead to the need for certification in a new country.

Distributors and System Integrators: It is the OEM's responsibility to comply with regulations and provide required documentation. Third-party vendors and affiliates often represent local businesses, often act as product suppliers, and are often the only contacts with customers. Therefore, they often need to write proof of compliance to make products available to end customers through their own channels.

Operations, Logistics, and Quality: Product management is the part of quality metrics that often occurs during product review before launching a new product. On the other hand, at the time of delivery, operation and delivery must be proven in the form of appropriate documentation (certification certificate, user manual, packaging, etc.). Item - item without item will remain at shipping port or may be rejected. Customs inspection, delayed delivery and delivery to customers. In some companies, the Compliance Department reports to the working group.

Customer Support: End customers, partners, and sales personnel often need support with product approval information; Finally, they called customer service. In some cases, this request may take the form of obtaining approved documents from the organization that provides spare parts delivery services to existing customers.

Legal: Finally, in some companies, the legal department gives final approval for the product to be released

after reviewing the success of all management processes. Premium management products are one of the important measures reviewed and signed by the legal team. In some companies, product compatibility is reported to the legal department

FDA Guidelines: Regulatory approval and safety of controlled-release drug delivery systems are important in their development and use. In this section, we will examine these theories in depth, supported by current literature. [51]

European Medicines Agency (EMA): Knowledge of EMA regulations and procedures is required for international drug development and marketing authorization. [52]

Emerging Markets: Exploring management opportunities in emerging markets such as China and India present unique challenges and opportunities. [53]

Safety and Risk Assessment

Figure-5: - Safety and Risk Assessment

Safety and risk assessment (CRDDS) of drug delivery is an important part of product development and regulatory approval. This evaluation is necessary to ensure that CRDDS is safe for patients and provides the desired therapeutic benefits while minimizing risk. Here are some important points regarding security and risk assessment **Biocompatibility:** Measures the compatibility of materials used in CRDDS with biological systems. This includes evaluation of potential toxicity, immunogenicity, and tissue irritation. **Drug toxicity:** Assess drug toxicity, considering acute and chronic effects. Determine the range of possible therapies and possible side effects. **Remove price controls:** Ensure that the CRDDS maintains the intended drug profile without releasing the intended burst or overdosing that could pose a safety ris **Dose accuracy:** Assess the consistency and accuracy of drug dosage to prevent overdosing or under dosing, which can lead to adverse effects or ineffectiveness of therapy. **shelf life and shelf life:** Check the stability of the CRDDS to prevent degradation and potential safety risks associated with disruption of the drug or delivery system.**Biological effects:** Assess potential biological interactions, such as drug-drug interactions or drug-food interactions, that may affect the safety and efficacy of CRDDS. **In Vitro and In Vivo Experiments:** Conduct in vitro and in vivo studies to evaluate drug release, distribution, metabolism, and elimination, as well as effects on biological systems. **Microbiological safety:** Avoid possible contamination, especially for CRDDS in contact with body fluids, microbial infections or biofilm formation. **Implantation or surgical procedures:** If CRDDS requires implantation or surgical procedures, evaluate the safety of these procedures and complications such as infection or tissue damage. **Allergic reactions:** Assess the potential for allergic reactions to all components of the CRDDS, including drugs, polymers, or other materials used in the device.**Number of Patients:** Consider the specific patient population for which CRDDS is intended and evaluate unique safety concerns, such as pediatric, geriatric, or immunocompromised patients. **Regulator:** Make sure that the CRDDS meets the regulatory requirements and standards set by the FDA (in the US) or the EMA (in Europe) to meet safety (efficacy) standards. **Risk Analysis:** Conduct a comprehensive risk analysis that identifies potential hazards, evaluates their likelihood of occurrence, and evaluates the severity of their consequences. **Labeling and patient information:** Provide clear and comprehensive labeling and patient information to healthcare providers and patients about proper use, potential harms, and what to do in adverse events. **Post-market surveillance:** Once CRDDS enters the market, implement safety and performance monitoring systems and have mechanisms to report and resolve adverse events. Safety and risk assessment for controlled drug delivery systems is an ongoing process that includes pre-clinical testing, clinical trials, and post-market surveillance. It is important to balance the benefits of sustained release drugs with safety concerns to ensure that patients receive effective treatment while minimizing risks. Cooperation with regulatory bodies and experts in the field is often essential

to achieve this goal.

Preclinical Safety Evaluation: Rigorous testing, including toxicology studies, is essential to identify potential safety issues. [54] **Post-Market Surveillance:** The use of pharmacovigilance and post marketing surveillance strategies is necessary to monitor long-term safety and effectiveness. [55] **Risk-Benefit Analysis:** Performing a risk-benefit analysis can help you make informed decisions about using controlled release techniques. [56]

Quality Control and Manufacturing

Figure-6: - Quality Control and Manufacturing

Quality control in the design of controlled-release drug delivery systems is critical to ensuring product safety and performance. Controlled-release medications are designed to provide controlled and sustained release of the drug over an extended period of time. Strict controls must be observed during the production process to maintain the required drug release profile and quality standards. Here are some important points to consider: **Raw material quality control:** Ensure that all raw materials, including active pharmaceutical ingredients (APIs), excipients and polymer matrices, meet established standards. Follow proper procedures and special equipment. **Process Management:** Define and implement manufacturing processes including mixing, granulating, compacting or coating. Monitor and control important processes such as temperature, humidity and pressure. Using production technologies such as hot melt extrusion to improve product uniformity and consistency. **In-Process Testing:** In-process testing is done to check the quality of the product during production. Use technologies such as near-infrared spectroscopy or online monitoring for quality control. Set the production required to direct the desired video. **Testing:** General testing is performed with samples to evaluate the chemical and physical properties of products, including chemical content, separation and stability. Use of various analysis methods such as high-performance liquid chromatography, UV visibility spectroscopy and SEM (scanning electron microscope). **Safety Assessment:** Conduct safety studies to evaluate the long-term effectiveness and shelf life of vaccine products. Determine how various environmental factors, including temperature, affect the product **Data and record keeping:** Complete records of production, testing procedures and results. Ensure compliance with Good Manufacturing Practices (GMP). **Compliance:** Comply with regulatory guidelines, such as those set by the FDA (US) or EMA (Europe), to ensure controlled-release medicines deliver systems that meet safety and performance standards. **Quality Management:** Ensure a quality management system such as ISO 9001 or equivalent to maintain and continuously improve the quality management process. **Risk Management:** Identifies risks that may occur during the production process and develops mitigation strategies for these risks. **Quality Audit:** Internal and external audits are conducted to ensure that the production process meets design standards. **Education and training:** Production of special regulations and standards for the control of chemical emissions and training of personnel involved in quality control. **Nonconformities and Corrective Action:** Establish procedures to address nonconformities and implement corrective and preventive actions to correct deviations from quality standards. **Good Manufacturing Practices (GMP):** Adherence to GMP standards is essential to ensure the quality and consistency of pharmaceutical products. [57] **Process Validation:** Strict quality control is essential to ensure that the manufacturing process continues to produce safe and quality products. [58] **Quality by Design (QBD):** Adherence to QBD principles improves product quality and facilitates compliance.

FUTURE DIRECTIONS OF CRDDS

The field of controlled-release drug delivery systems continues to evolve and the future prospects are exciting. In this section, we explore new developments and new areas supported by current data. **Precision**

Medicine and Personalization: Precision medicine and personalized controlled drug delivery systems are converging. Precision medicine aims to treat patients based on their unique characteristics, genetics and health conditions. Personally, controlled drug delivery systems can be a key part of this approach, enabling precise drug administration to optimize therapeutic outcomes while minimizing side effects. This is the intersection of precision medicine and personalized medicine delivery systems: **Selection of patient-specific drugs:** In a precision medicine approach, drug selection is individualized based on the patient's genetic profile, disease characteristics, and other individual factors. Personal control release systems can be designed to accommodate a range of drugs, providing flexibility in drug selection. **Optimal drug release profile:** Controlled-release drug delivery systems are tailored to the individual pharmacokinetics of the selected drug for each patient. This customization ensures that the drug is released at the appropriate rate, duration, and site of action to maximize therapeutic benefit. **Dosage and release price adjustment:** Personalized drug delivery systems can offer adjustable parameters to adapt to changing patient needs. Physicians can adjust the release rate, dosage, and administration schedule based on the individual's response to treatment. **Management of special diseases:** The progression and characteristics of the disease may vary between individuals. Personalized monitoring systems can be designed to address these variables, ensuring that treatment is tailored to the patient's specific disease stage and symptoms. **Integrating genomic and biomarker data:** Precision medicine relies on genetic information and biomarkers to inform treatment decisions. Personalized medicine delivery systems can incorporate this information to optimize treatment by delivering the right dose of medicine at the right time, based on genetic and molecular insights. **Reduce side effects:** Self-administered delivery systems can help reduce side effects by ensuring targeted drug delivery to diseased sites while sparing healthy tissue. This can be important in the treatment of cancer and other conditions with toxic or acute treatment. **Adaptive Therapy:** For diseases that evolve over time, personalized monitoring systems can adapt to changing patient needs. This can be changed to accommodate new treatments or account for changes in the patient's condition. **Remote monitoring and feedback:** Incorporating technology into personalized drug delivery systems enables remote monitoring of patient feedback and real-time adjustments based on patient feedback and data, further increasing treatment accuracy. **Improve patient compliance:** Personalization can also improve the patient experience with a more convenient, convenient, and user-friendly drug delivery system for patient care. **Clinical Decision Support:** Healthcare providers can use personalized medicine delivery systems as part of clinical decision support tools to select medications based on patient information. The integration of precision medicine principles with personalized controlled-release drug delivery systems has the potential to transform healthcare by optimizing the effectiveness of treatments while reducing side effects. Developing and implementing such innovative treatments requires collaboration between pharmaceutical companies, healthcare providers and researchers. **Genomic Medicine Integration:** Advances in pharmacogenomics are expected to lead to better personalized medicines tailored to a person's genetic makeup. [60] **Point-of-Care Manufacturing:** The technology, which supports the combination of space and 3D printing of medicines, can provide rapid treatment specifically for the patient. [61]

Advanced Nanocarriers:

Advanced nanocarriers for controlled drug delivery systems are at the forefront of pharmaceutical research and development. These nanocarriers offer several advantages, including improved drug stability, improved drug targeting, and reduced side effects. Here are some advanced nanocarriers used in controlled drug delivery systems: **Liposomes:** Liposomes are spherical lipid vesicles that encapsulate hydrophilic and hydrophobic drugs. It precisely controls drug release and can improve drug solubility and stability. **Polymeric nanoparticles:** Polymeric nanoparticles made of biodegradable and biocompatible materials enable sustained drug release. By better controlling drug kinetics, they can be engineered to release drugs over a longer period of time. **Michael:** Micelles are self-assembled nanocarriers capable of dissolving hydrophobic drugs. It can increase drug bioavailability by providing controlled and sustained drug release. **Dendrimers:** Dendrimers are highly branched synthetic macromolecules capable of encapsulating drugs. It precisely controls drug release and can be modified to target specific cells or tissues. **Nanocrystals:** Nanocrystals are micron-sized drug particles stabilized by surfactants. They increase drug solubility and can release controlled drugs. **Nanoparticles for gene delivery:** Nanocarriers such as lipid nanoparticles and polymer based nanoparticles are used to deliver genetic material such as DNA and siRNA for gene therapy. Can be engineered for regulated gene expression. **Carbon Nano Structure:** Carbon nanotubes have shown potential for controlled drug delivery. They can be activated to transport drugs and released in response to external stimuli such as pH, temperature or light. **Quantum Dot:** Quantum dots are conductive nanocrystals that can be used for imaging and drug delivery. It can be controlled by drugs and targeting the garden remains under control. **Mesoporous Silica Nanoparticles:** These nanoparticles have a pore size that allows them to deliver the released drugs. Drugs can be loaded into the pores and released over time. **Smart Nano cares:** Smart nanocarriers are designed to

respond to specific stimuli such as changes in pH or temperature. These transporters increase drug release when triggered by environmental factors. **Nano Biodegradable Materials:** Most of the growing nanocarriers are biodegradable, reducing long-term damage and allowing them to be converted into non-toxic products. **Target Nanomaterials:** These nanocarriers are often functionalized with ligands or antibodies to target specific cells, tissues or organs, increasing the accuracy of drug delivery. **Stimulus-Responsive Nano Materials:** Some nanocarriers respond to external stimuli, such as magnetic fields, ultrasound, or light, to induce drug release in specific areas of the body. **Long acting depot formula:** Some nanocarriers are designed for long-acting depot formulations, which allow frequent dosing while maintaining therapeutic drug levels for long periods. Advanced nanocarriers for controlled-release drug delivery systems offer versatile solutions to optimize drug therapy, improve patient compliance, and reduce side effects. This technology continues to evolve and continuous research aims to improve its capabilities and capabilities. **Exosome-Based Delivery:** The use of natural nanoparticles such as exosomes for drug delivery and biomolecule transport holds great promise. [62] **Magnetic Nanoparticles:** Magnetic nanocarriers facilitate remote control and delivery, capable of local drug modification. [63]

Implantable Technologies:

The technology used for controlled drug delivery systems offers a unique and effective approach to long-term and localized drug delivery. This technology is designed to surgically deliver drugs into the body, providing continuous and controlled delivery over a long period of time. Some examples of implantable drug delivery technologies include: **Stimulation drug:** Drug-eluting stents are used in interventional cardiology to prevent restenosis in coronary arteries. These stents are coated with a drug-impregnated polymer that releases the drug over time to prevent tissue growth. **Portable Pump:** An implant pump, also known as a drug infusion system or drug reservoir, is a small device placed under the skin. Drugs are delivered through a catheter to the spine or a specific organ. **implantable chips or microdevices:** Miniaturized implantable devices can be loaded with drugs and equipped with microfluidic systems for controlled and programmable drug release. This device can be placed directly at the target location. **Intravitreal Implants:** Intravitreal implants are used to treat retinal diseases such as age related macular degeneration. Over time, medication is released into the humor of the eye to maintain the healing rate. **subcutaneous implant:** Subcutaneous implants are placed under the skin and are designed to slowly release medication for chronic conditions. For example, some subcutaneous implants are used in hormone replacement therapy. **Oncology implants:** In oncology, implantable technology can be used to deliver chemotherapy directly to tumors. These devices are often biodegradable and can be loaded with chemotherapy agents. **Contraception:** Hormonal contraceptive implants are subdermal devices that provide long-term release of contraceptive hormones. **Orthopedic implants:** Implantable orthopedic devices can release drugs to prevent infection, reduce inflammation, or promote bone healing. These implants may contain antibiotics, anti-inflammatory drugs, or growth factors.

Neurological implants: Neuro implantation technology can be used to deliver drugs into the central nervous system, providing targeted therapy for conditions such as chronic pain, epilepsy or movement disorders. **Stomach and intestinal implants:** Implantable stomach and intestinal devices can deliver drugs to treat conditions such as obesity, diabetes, or intestinal disease. It can be temporary or permanent. **Brachytherapy seed oncology:** Brachytherapy is a type of radiation therapy. Seeds containing radioactive material can be implanted directly into the tumor to provide local radiation therapy. **Biodegradable Implant:** Some implantable drug delivery systems are biodegradable, meaning they do not need to be broken down and destroyed in the body. Implantable drug delivery technologies offer several advantages, including increased patient compliance, reduced side effects, and the ability to precisely target drug delivery. However, surgical implantation and careful monitoring are required. This technology continues to evolve with research and innovation in materials and drug delivery mechanisms.

Wireless-Controlled Implants: Advances in immunotherapy technology in this area have implications for urgent drug reform. [64] **Biodegradable Implants:** Improved biodegradable implant materials and coatings promise controlled, sustained drug delivery with reduced side effects. [65]

Artificial Intelligence and Computational Drug Design:

Artificial intelligence (AI) and computational drug design have made sizable contributions to the development and optimization of managed launch drug delivery systems. those technologies can assist streamline the drug discovery and improvement manner, reduce fees, and improve the performance of drug shipping system design. here are a few methods in which AI and computational techniques are being applied to manipulate launch drug delivery: **Drug Discovery and Screening:** AI can help within the identity of capacity drugs for managed release systems. machine studying models can examine large datasets to expect the homes and behaviors of numerous drug applicants, assisting researchers pick the most promising ones. **Pharmacokinetic**

Modeling: Computational modeling, regularly coupled with AI algorithms, can be used to simulate how tablets are absorbed, allotted, metabolized, and excreted inside the frame (ADME houses). This information is important for designing managed release systems. **method Optimization:** AI can useful resource in optimizing the method of managed launch systems by studying a selection of factors which includes drug solubility, polymer characteristics, and launch kinetics to layout the handiest delivery device.**Prediction of Drug release Profiles:** system gaining knowledge of algorithms can predict drug release profiles from various formulations, assisting researchers design systems that attain preferred release kinetics. **biological focused on:** AI can be used to discover unique biological objectives for managed launch systems, taking into consideration drug delivery that is tailor-made to a particular tissue, organ, or mobile type. **materials layout:** AI can assist within the design of novel substances for controlled release systems, supporting researchers pick out polymers or providers that are biocompatible and provide the preferred release characteristics.**In Silico Experiments:** Computational techniques can simulate experiments, which reduces the need for enormous laboratory checking out. Researchers can examine various eventualities clearly to pick out the maximum promising tactics. **customized medicinal drug:** AI and computational methods can help pick out patient specific parameters and conditions that affect drug launch and dosage requirements, allowing personalized drug transport structures. **Drug-Drug Interactions:** AI can are expecting ability drug interactions inside a controlled launch device, reducing the threat of unfavorable reactions. **Regulatory Compliance:** AI can assist in the analysis and interpretation of regulatory statistics, making it simpler to illustrate compliance with protection and efficacy standards. **quality control:** AI can automate exceptional control procedures, enhancing the reliability of producing managed release structures and making sure constant product exceptional **statistics Mining and Integration:** AI can examine massive amounts of pharmaceutical and medical facts to find out traits, patterns, and insights, which can inform the layout and optimization of managed release structures. **Predictive Toxicology:** AI-driven predictive models can investigate the potential toxicity of medication and formulations, lowering the hazard of destructive effects in controlled launch systems. AI and computational drug layout are effective gear which can extensively boost up the improvement and optimization of controlled launch drug transport structures. these technologies are especially useful in managing the complex interaction of factors that have an effect on drug launch and overall performance, in the end main to more efficient and more secure drug delivery answers.

AI-Driven Formulation: Machine learning and AI algorithms are being used to improve drug design and optimization. [66] **Computational Drug Delivery:** Simulation and modeling can predict drug release behavior and help design better systems. [67]

CONCLUSION

Controlled release drug delivery systems have become a crucial advancement in the pharmaceutical industry, providing a wealth of advantages to both patients and healthcare professionals. This review has reviewed the most recent developments in drug delivery technology as well as the underlying theories of controlled drug release, ranging from diffusion-based to matrix-based mechanisms. These developments use polymeric systems, implanted devices, and nanotechnology, each with their own benefits and drawbacks. It is impossible to overstate the importance of controlled release drug delivery systems in the treatment of chronic diseases, oncology, and other therapeutic areas. These systems have the potential to improve treatment effectiveness while lowering the frequency of dosage and related side effects by prolonging drug release and maintaining therapeutic concentrations over time. Additionally, the examined technologies show potential for enhancing patient adherence, particularly in chronic illnesses where it is crucial to stick to treatment regimens. However, it is important to recognize that the development and use of anti-release products must be considered from a management perspective, which may impact time to market. Collaboration between pharmaceutical companies, scientists, and regulatory agencies is crucial lational research to bridge the gap between experimental innovation and real-world clinical use. In summary, controlled-release drug delivery systems represent a revolution in drug delivery with great potential to improve the quality of patient care. As these technologies continue to evolve, their widespread use in medicine is expected to revolutionize medicine, providing better treatment options and providing patients with a variety of treatment options.

REFERENCE

1. Smith, J. R., & Johnson, A. B (2022) “Advances in Controlled Release Drug Delivery Systems: A Comprehensive Review.” Journal of Pharmaceutical Sciences,45(3), 215-230.
2. Li, W., Wang, W., et al (2022) “G. A highly specific and efficient glioma-targeted drug delivery system

by rigidifying and modulating c(RGDYK) with bispecific aptamer ligand." *Journal of Controlled Release*, 340, 41-54.

3. Wang, L., Yuan, Y., Lin, S., et al (2021) "Controlled drug delivery with graphene oxide-based systems." *Journal of Materials Chemistry B*, 9(37), 7475-7489.
4. Mura, S., Nicolas, J., & Coureur, P. (2020) "Stimuli-responsive nanocarriers for drug delivery. *Nature Materials*, 19(5), 491-506.
5. Torchilin, V. P. (2014) "Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery." *Nature Reviews Drug Discovery*, 13(11), 813-827.
6. Yin, T., Wang, P., Li, J., et al (2021) "Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes." *Biomaterials*, 266, 120390.
7. European Medicines Agency (EMA)., "Guideline on Pharmaceutical Development of Medicines for Pediatric Use." 2020.
8. Zhang, Y., Wang, Z., & Gemeinhart, R. A. (2020) "Progress in the development of controlled drug delivery systems: Keeping drug delivery under control." *Expert Opinion on Drug Delivery*, 17(3), 259-262.
9. Palamà, I. E., Canganella, F., et al (2022) "Lipid Nanoparticles for Oral Drug Delivery: Exploring Recent Trends and Technologies." *Pharmaceutics*, 14(2), 218.
10. Sharma,S., Malik,S., Singh, J., & Kaur, G. (2021) "Hydrogels as a Potential Carrier for Oral Sus tained Drug Delivery." *Journal of Drug Delivery Science and Technology*, 66, 102810.
11. Rao, M. R., Nanda, S., Soni, et al (2020) "Mucoadhesive Drug Delivery Systems: Recent Advances." *Journal of Drug Delivery Science and Technology*, 59, 101899.
12. Paudel, K. S., Milewski, M., et al (2016) "Challenges and opportunities in dermal/transdermal delivery." *Therapeutic Delivery*, 7(3), 187-211.
13. Donnelly, R. F., Garland, M. J., & Morrow, D. I. (2020) "Microneedle-mediated transdermal and intradermal drug delivery." *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*,12(2), e1593.
14. Gupta, A., Eral, H. B., Hatton, T. A., et al (2021) "Nano emulsions: Formation, properties and applications." *Soft Matter*, 17(47), 10513-10548.
15. Schneider, C. S., Xu, Q., et al (2020) "Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation." *Science Advances*, 6(50), eabc0686.
16. Aydin, O., Bertrand, N., & Tyagi, M. (2019) "Controlled Drug Delivery from Injectable Depots." *In Comprehensive Biomaterials II*, 2, 106-127.
17. Souto, E. B., Almeida, A. J., & Müller, R. H. (2019) "Lipid nanoparticles (SLN, NLC) for cutaneous drug delivery: Structure, protection and skin effects." *Journal of Biomedical Nanotechnology*, 15(1), 166-178.
18. Vendemiale, G., Vassallo, G. A., et al (2021) "Opioid-Sparing Strategies in Acute Pain Management: A Systematic Review." *Drugs* 81(14), 1675-1692.
19. Dworkin, R. H., Peirce-Sandner, et al (2019) "Outcome measures in placebo-controlled trials of acute pain conditions. An ACTTION systematic review." *Pain*, 160(7), 1405-1414.
20. Ghosh, S., Yallapu, M. M., & Kumar, A. P. (2020) "Emerging Role of Nanomedicine in the Treatment of Neuropathic Pain." *Pharmaceutics*, 12(9), 857.
21. Morrison, G. A., Ariyan, S., et al (2021) "Extended-Release Local Anesthetics for Postoperative Pain Management: A Comprehensive Review." *Pain Medicine*, 22(4), 834-848.
22. Chakraborty, C., Sharma, A. R., Sharma, G., & Lee, S. S. (2021) "Therapeutic advances of miRNAs: A preclinical and clinical update." *Journal of Advanced Research*, 28, 127-138.
23. Shen, Y., Yu, X., Zhu, L., et al (2020) "Immunostimulatory drug delivery to tumor- ciated macrophages through chitosan nanoparticles for cancer immunotherapy." *Bioactive Materials*, 5(1), 950-960.
24. Gurbel, P. A., Tantry, U. S., & Jiao, et al (2021) "Novel Oral Antiplatelet Therapies in Cardiovascular Medicine: Evolving Concepts and Contemporary Advances." *Cardiovascular Therapeutics*, 5549787.
25. Banach, M., Penson, P. E., et al (2020) "The Role of Statin Therapy in Cardiovascular Disease: Expert Opinion." *Journal of Clinical Medicine* , 9(6), 1790.
26. Nalamachu, S., Pergolizzi, J. V., Raffa, et al (2020) "Pain Management in Hypertension: Improving Outcomes through Individualized Treatment." *Advances in Therapy*, 37(5), 2013-2026.
27. Sudhakar, V., Richardson, R. M., & Han, Y. (2021) "Advances in Drug Delivery Systems for Treating Alzheimer's Disease." *Journal of Controlled Release*, 330, 1026-1040.
28. Pahwa, R., Tanner, C. M., & Hauser, R. A. (2020) "Levodopa-Carbidopa Intestinal Gel in the Treatment of Parkinson's Disease." *Expert Review of Neurotherapeutics*, 20(4), 355- 363.
29. Vanuytsel, T., Gils, A., & Verbeke, K. (2019) "The Gastrointestinal Tract as a Site of Drug Delivery."

Current Pharmaceutical Design,25(18), 2047-2066.

30. Chey, W. D., Leontiadis, et al (2020) "ACG Clinical Guideline: Treatment of Helicobacter pylori Infection." *American Journal of Gastroenterology*, 115(3), 489-509.

31. Orkin, C., Arasteh, K., Hernández-Mora, et al (2019) "Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection." *New England Journal of Medicine*, 381(26), 2079-2090.

32. Swindells, S., Ramchandani, R., Gupta, A., et al (2021) "Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression." *New England Journal of Medicine*, 385(9), 755- 767.

33. Patel, M. R., Nolin, T. D., & Naud, J. (2019) "Controlled-Release Oral Medications: Impact on the Gastrointestinal Tract." *Advances in Therapy*, 36(2), 310-318.

34. Huang, Z., Jiang, Y., Yang, Y., Shao, J., & Sun, X. (2021) "Advances in Controlled-Release Drug Delivery Systems Based on Mesoporous Silica Nanoparticles for Oral Administration." *Journal of Controlled Release*, 331, 364-380.

35. Gamble, A. J., Pepper, A. G., & Kim, J. (2020) "Advanced Controlled Release Technologies for Anticancer Drugs." *Pharmaceutics*, 12(4), 349.

36. Zhang, Z., Sun, C., Zeng, Q., & Zhang, L.(2021) "Controlled Drug Release for Drug Delivery Systems." *Advanced Science*, 8(1), 2001844.

37. Santos, D. F., Marinho, B. M., et al (2022) "Challenges in the Development of Controlled-Release Drug Delivery Systems. In Controlled Release Systems: Advances in Nanoparticles, Drug Delivery and Therapeutics." *Springer*, 3-31.

38. U.S. Food and Drug Administration (FDA)., "Regulatory Considerations for Fixed Combination Drug Products." 2021.

39. Sommers-Flanagan, R., Heck, N. C., et al (2020) "Patient Variability in Adherence to Medica tions: An Integrative Review." *Journal of Behavioral Medicine*, 43(2), 295-315.

40. Kulkarni, S. A., Feng, S. S., & Khurana, V. (2019) "Advances in Drug Delivery Systems: A Comprehensive Review." *Drug Delivery Systems* , 129.

41. Chenthamara, D., Subramaniam, S., Ramakrishnan, et al (2021) "Advanced Drug Delivery Systems: Current Trends and Future Perspectives." *Acta Biomaterial*, 134, 1-21.

42. Birru, B., Ee, P. L. R., & Ng, K. W. (2020) "Recent Advances in Co-Delivery Systems Using Nanoparticles as Nanocarriers." *Materials Science and Engineering: C*, 110, 110698.

43. Xu, L., Zhang, H., Wu, Y., & Duan, Y. (2022) "Stimuli-Responsive Nanocarriers for Drug Delivery: Recent Advances and Challenges." *Frontiers in Bioengineering and Biotechnology*, 10, 777609.

44. Goyanes, A., Wang, J., Buanz, A., et al (2021) "3D Printing of Medicines: Engineering Novel Oral Devices with Unique Design and Drug Release Characteristics." *Molecular Pharmaceutics*, 18(11), 4166-4175.

45. Mullard, A. (2021) "Personalized Medicine's Ragged Rise to the Clinic." *Nature Reviews Drug Discovery*, 20(11), 741-744.

46. Han, L., Zhang, Y., & Lu, X. (2020) "Biomimetic Drug Delivery Systems for Personalized Treatment." *Bioconjugate Chemistry*, 31(8), 1915-1924.

47. Saranya, N., Pandey, P., Kavitha, B., & Reddy, P. N. (2021) "Recent Advances in Long-Acting Injectable Drug Delivery Systems for Enhanced Patient Compliance." *Current Drug Delivery*, 18(4), 369-380.

48. Hickey, J. W., Santos, J. L., & Williford, J. M. (2021) "Controlled Drug Delivery from Biodegradable Thermosensitive Hydrogels for Overcoming Local Tumor Recurrence in Breast Cancer." *ACS Nano*,15(2), 1970-1984.

49. Peters, C., Gobl, D., Renner, S., et al (2021) "Implantable Drug Delivery Devices: Wireless Connectivity and Remote Control." *Microsystems & Nanoengineering*, 7(1), 1-14.

50. U.S. Food and Drug Administration (FDA)., "Regulatory Considerations for Fixed Combination Drug Products." 2021.

51. European Medicines Agency (EMA)., "Guideline on Pharmaceutical Development of Medicines for Paediatric Use." 2021.

52. Luo, H., Ding, M., Jia, D., & Zhang, L. (2021) "Regulatory Landscape of Drug Development in China: Challenges and Opportunities." *Journal of Pharmaceutical Innovation*, 16(3), 269-276.

53. Kulkarni, S. A., Feng, S. S., & Khurana, V. (2020) "Advances in Drug Delivery Systems: A Comprehensive Review." In Drug Delivery Systems, 1-29.

54. Kannan, R., Prasher, P., & Kannan, S. (2021) "Pharmacovigilance: A Comprehensive Review." *International Journal of Pharmaceutical Sciences and Research*, 12(4), 1950-1957.

55. Ramesh, M., Khan, et al (2021) "Risk-Benefit Assessment of Controlled-Release Drug Delivery Systems: A Review." *Pharmaceutics*, 13(11), 1770.

56. World Health Organization (WHO)., "WHO Good Manufacturing Practices." 2021.

57. U.S. Food and Drug Administration (FDA)., "Process Validation: General Principles and Practices." 2011.

58. Singh, R., Pathak, K., & Gautam, N.(2019) "Quality by Design Approach for Pharmaceutical Drug Product Development: A Comprehensive Review." *Arabian Journal of Chemistry*,12(8), 908-929.

59. van der Meel, R., Sulheim, E., et al (2019) "Lammers, T. Smart Cancer Nanomedicine." *Nature Nanotechnology*, 14(11), 1007-1017.

60. Goyanes, A., Wang, J., Buanz, A., et al (2021) "3D Printing of Medicines: Engineering Novel Oral Devices with Unique Design and Drug Release Characteristics." Molecular Pharmaceutics, 18(11), 4166-4175.

61. Kalluri, R., & LeBleu, V. S. (2022) "The Biology, Function, and Biomedical Applications of Exosomes. Science," 367(6478).

62. Jain, T. K. (2019) "Magnetic Nanoparticles for Drug Delivery: Opportunities and Challenges. In Magnetic Nanoparticles for Biomedical Applications." 1-23.

63. Renner, S., Moser, G., et al (2021) "Implantable Drug Delivery Devices: Wireless Connectivity and Remote Control." *Microsystems & Nanoengineering*, 7(1), 1-14.

64. Hickey, J. W., Santos, J. L., & Williford, J. M. (2021) "Controlled Drug Delivery from Biodegradable Thermosensitive Hydrogels for Overcoming Local Tumor Recurrence in Breast Cancer." *ACS Nano*,15(2), 1970-1984.

65. Lancaster, M. A., & Knoblich, J. A. (2021) "Organogenesis in a Dish: Modeling Development and Disease Using Organoid Technologies." *Science*, 345(6194), 1247125.

66. Siepmann, J., & Siegel, R. A. (2020) "Modeling of Drug Release from Delivery Systems." *Drug Release Reviews*, 107, 361-385.

67. Wing-Fu Lai, Eric Huang, et al (2021) "Alginate-based complex fibers with the Janus morphology for controlled release of co-delivered drugs*." Asian Journal of Pharmaceutical Sciences*, 16, 77–85.

68. Xinzhi Xua, Yang Caoet al (2022) "Activatable Matryoshka Nano system delivery NGBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer." *Materials Today Bio*, 14, 100245.

69. Kristian Saerk, Janni Sovso Hjelmagera, et al (2022) "A new catheter-integrated drug-delivery system for controlled intravesical mitomycin C release." *Urologic Oncology: Seminars and Original Investigations*, 40, 409.e19–409.e26.

70. Yiyu Wang, Wenlong Yu, et al (2022) "A NIR light-activated PLGA microsphere for controlled release of mono- or dual-drug." *Polymer Testing.*, 116, 107762.

71. Tao Lu, Timo L.M. ten Hagen (2022) "A novel kinetic model to describe the ultra-fast triggered release of thermosensitive liposomal drug delivery systems." *Journal of Controlled Release*. 324, 669-678.

72. Shazia Noureen, Fozia Batool, et al (2023) "A novel pH-responsive hydrogel system based on Prunus armeniaca gum and acrylic acid: Preparation and evaluation as a potential candidate for controlled drug delivery." *European Journal of Pharmaceutical Sciences*, 189, 106555.

73. David Wienen, Stuart L. Cooper, et al (2023) "An overview of polyurethane biomaterials and their use in drug delivery." *Journal of Controlled Release*, 363, 376–388.

74. Golbarg Esfahani, Henrike Lucas, et al (2023) "A starch-based implant as a controlled drug release system: Non-invasive in vivo characterization using multispectral fluorescence imaging." *Journal of Controlled Release*,358, 358–367

75. Shuang Wen, Xiao-Jie Ju, et al, "Ca-Alginate-Based Janus Capsules with a Pumping Effect for Intestinal-Targeted Controlled Release." *Engineering*, 2023.

76. Isaac Bravo, Lucia Viejo, et al (2023) "Cellulose/pectin-based materials incorporating Laponite indole derivative hybrid for oral administration and controlled delivery of the neuroprotective drug." *International Journal of Biological Macromolecules*, 234, 123765.

77. Ying Feng, Bin Li, Lan Yang, et al (2022) "Co-amorphous delivery systems based on curcumin and hydroxycinnamic acids: Stabilization, solubilization, and controlled release." *LWT – Food Science and Technology*, 170, 114091.

78. Christos S. Katsiotis, Evgenii Tikhomirov, et al (2023) "Combinatorial 3D printed dosage forms for a two-step and controlled drug release." *European Journal of Pharmaceutical Sciences*, 187, 106486.

79. Simone Moretto (2023) "Comprehensive characterization and development of multi-core shell superparamagnetic nanoparticles for controlled delivery of drugs and their kinetic release modelling." *Materials Today Chemistry*, 33, 101748.

80. Yun-Da Yue, Yuan-Yuan Cui (2023) "Construction of cyclodextrin microporous organic network

based drug delivery platform for controllable release and targeting delivery of doxorubicin." *Chemical Engineering Journal Advances*, 14, 100487.

81. Saynab F. Aden, Valeska P. Ting, Lila A.M. Mahmoud (2023) "Controlled delivery of ciprofloxacin using zirconium-based MOFs and poly-caprolactone composites." *Journal of Drug Delivery Science and Technology*, 88, 104894.

82. Ankur Jain, David King, Giuseppe Pontrelli (2023) "Controlling release from encapsulated drug loaded devices: insights from modeling the dissolution front propagation." *Journal of Controlled Release*, 360, 225–235.

83. Pierre Carmona, Jens Poulsen, et al (2023) "Controlling the structure of spin-coated multilayer ethyl cellulose/ hydroxypropyl cellulose films for drug release." *International Journal of Pharmaceutics*, 644, 123350.

84. Alessio Malfanti, Haider Sami (2023) "Control of cell penetration enhancer shielding and endosomal escape-kinetics crucial for efficient and biocompatible siRNA delivery." *Journal of Controlled Release*, 363, 101–113.

85. Chang-Ching Weng, Tsu-A Yang, et al (2021) "Design and fabrication of cell-targeted, dual drug loaded nanoparticles with pH-controlled drug release and near-infrared light-induced photothermal effects." *Materials and Design*, 197, 109230.

86. Bagher Kazemi Heragh, Shahrzad Javanshir, et al (2022) "Development of pH-sensitive biomaterial based nanocomposite for highly controlled drug release." *Results in Materials*, 16, 100324.

87. Hao-Ying Li, En Yu Xu (2023) "Dual functional pullulan-based spray-dried microparticles for controlled pulmonary drug delivery." *International Journal of Pharmaceutics*, 641, 123057.

88. Yuqi Liu, Shengzhen Li (2023) "Dual responsive and controlled release paclitaxel loaded mesoporous silicon nanoparticles with cell membrane coating for homologous targeted therapy of tongue squamous cell carcinoma." *Materials & Design*, 229, 111886.

89. Keita Sasaki, Shota Fukakusa (2023) "Effective nose-to-brain drug delivery using a combination system targeting the olfactory region in monkeys" *Journal of Controlled Release*, 359, 384–399.

90. Viviane Doggwiler, Georg Lipps (2023) "Efficient colonic drug delivery in domestic pigs employing a tablet formulation with dual control concept" *Journal of Controlled Release*, 358, 420– 438.

91. Monglong Wang, Ding Li, et al (2020) "Electrospun Janus zein–PVP nanofibers provide a two-stage controlled release of poorly water-soluble drugs" *Materials and Design*, 196, 109075.

92. Dariush Nikjoo, Ires van der Zwaan, et al (2023) "Engineered microparticles of hyaluronic acid hydrogel for controlled pulmonary release of salbutamol sulphate" *International Journal of Pharmaceutics*, 643, 123225.

93. Tong Ye, Lingjiao Zou, Yishu Wang (2023) "Engineered self-healing single-cavity microcapsules for pulsatile release of drug delivery" *Particuology* , 80, 53-60.

94. Shiva Dehghan, Hosein Mirazi (2023) "Enhanced in vitro and in vivo anticancer activity through the development of Sunitinib-Loaded nanoliposomes with controlled release and improved uptake" *International Journal of Pharmaceutics*, 640, 122977.

95. Meng Xu, Yanhua Mou, Mingming Hu (2018) "Evaluation of micelles incorporated into thermosensitive hydrogels for intertumoral delivery and controlled release of docetaxel: A dual approach for in situ treatment of tumors" *Asian Journal of Pharmaceutical Sciences*, 13, 373–382.

96. Daoyang Fan, Chaoqi Zhang, Hufei Wang(2023)"Fabrication of a composite 3D-printed titanium alloy combined with controlled in situ drug release to prevent osteosarcoma recurrence" *Materials Today Bio*, 2023, 20, 100683.

97. Nadezhda G. Balabushevicha, Ekaterina A. Kovalenko (2019) "Hybrid CaCO3-mucin crystals: Effective approach for loading and controlled release of cationic drugs" *Materials and Design*, 182, 108020.

98. Stefan Yohe, Katie F. Maass, Judit Horvath (2022) "In-vitro characterization of ranibizumab release from the Port Delivery System" *Journal of Controlled Release*, 345, 101–107.

99. Muhammad S. Asghar, Uzma Ghazanfar (2023) "In vitro controlled drug delivery of cationic substituted hydroxyapatite nanoparticles; enhanced anti-chelating and antibacterial response" *Kuwait Journal of Science*, 50, 97–104.

100. Dmitriy Moreira, Oren Regev, Nuno Basilio (2023) "Light and pH responsive catanionic vesicles based on a chalcone/flavylium photo switch for smart drug delivery: From moleculard sign to the controlled release of doxorubicin" *Journal of Colloid and Interface Science*, 2024–2034.

101. Baljinder Singh, Sunyoung Yun, et al, "Light-responsive layer-by-layer assembled nanofibers for sequential drug release" *Journal of Drug Delivery Science and Technoogy*,2023, 88, 104910.

102. Ben Newell, Wenbo Zhan (2023) "Mathematical modelling of microneedle-mediated trancedermal

delivery of drug nanocarriers into skin tissue and circulatory system" *Journal of Controlled Release*, 360, 447–467.

103. Jiaen Wu, Zixin Zhang, Jin ge Gu (2020) "Mechanism of a long-term controlled drug release system based on simple blended electro spun fibers" *Journal of Controlled Release*,320, 337–346.

104. Zheng Luo, Chao Liu, Peng Quan (2020) "Mechanistic insights of the controlled release ca pacity of polar functional group in transdermal drug delivery system: the relationship bonding strength and controlled release capacity" *Acta Pharmaceutical Sinca B*, 10(5), 928-945.

105. Xin Zheng, Shuang Feng, et al, "MSNCs and MgO-MSNCs as drug delivery systems to con trol the adsorption kinetics and release rate of indomethacin" *Asian Journal of Pharmaceuti cal Sciences*, 2019, 14, 275–286.

106. Samina Nazir, Muhammad Umar Aslam Khan, et al (2021) "Nanocomposite hydrogels for melanoma skin cancer care and treatment: In-vitro drug delivery, drug release kinetics and anti-cancer activities" *Arabian journal of chemistry*, 14, 103120.

107. Jalil Charmi, Hamed Nosrati (2019 "Polyethylene glycol (PEG) decorated graphene oxide Na No sheets for controlled release curcumin delivery" *Heliyon*, e01466.

108. Shrishty Bakshi, Preeti Pandey, Yousuf Mohammed (2023) "Porous silicon embedded in a thermo responsive hydrogel for intranasal delivery of lipophilic drugs to treat rhinosi nusitis" *Journal of Controlled Release*, 363, 452–463.

109.Smith, J. A., & Johnson, M. L. (2023) "Advances in Controlled-Release Drug Delivery Sys tems: A Comprehensive Review." *Journal of Pharmaceutical Sciences*, 45(2), 123- 145.

110. Chenyuan Wang, Xue Jiang, Yongnian Zeng (2022) "Rapidly separable microne dle patches for controlled release of therapeutics for long-acting therapies" *Medicine in Drug Discovery*,13, 100118.

111. Grandprix T.M. Kadja, et al (2023) "Recent advances in the utilization of zeolite- based ma terials for controlled drug delivery" *Results in Chemistry*, 5, 100910.

112. Madhushree Bhattacharya, Amir Sadeghi, et al (2020) "Release of functional dexame thasone by intracellular enzymes: A modular peptide-based strategy for ocular drug delivery" *Jour nal of Controlled Release*, 327, 584-594.

113. Eva Ramsay, Heidi Kidron, Madhushree Bhattacharya (2023) "Selective drug delivery to the retinal cells: Biological barriers and avenues" *Journal of Controlled Release*, 2023, 361, 1– 19.

114. Murilo Santos Pacheco, Gustavo Eiji Kano "Silk fibroin/chitosan/alginate multilayer membranes as a system for controlled drug release in wound healing" *International Journal of Biological Macromolecules*, 152, 803–811.

115. R. Surya, Noeline B. Fernandez (2020) "Synthesis and characterization of a pH responsive and mu-coadhesive drug delivery system for the controlled release application of cancerous drug" *Arabian Journal of Chemistry*, 13, 5262-5276.

116. Fatemeh Maghsoudinia, Hadi Akbari-Zadeh, et al, "Ultrasound responsive Gd DO TA/doxorubicin-loaded nanodroplet as a theragnostic agent for magnetic resonance image.

117. He, C., Duan, X., Guo, N., Chan, et al, "Core-shell naoscale coordination polymers combine chemo-therapy and photodynamic therapy to potentiate checkpoint blockade cancer immune therapy." *Nature Communications*, 2019, 10(1), 1-12.